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c
f
tionIntroduction
It is estimated that 5%–10% of breast cancer is hereditary with
60%–70% of those arising from a Breast Cancer gene mutation in
clinical practice (BRCA)1 or BRCA2 mutation.1 Women with
RCA1 or BRCA2 mutations have a 55%–85% lifetime risk of
nvasive breast cancer. Among women with BRCA1, 36%–63% de-
elop ovarian cancer and among patients with BRCA2 10%–27%
evelop ovarian cancer.2 BRCA1-related breast cancers tend to be of
he basal subtype, with predominant lymphocytic infiltration, and
re often more aggressive and associated with negative prognostic
actors. They are usually Estrogen (ER)/Progesterone (PR)/
ER2neu negative.3 BRCA2-related breast cancers tend to be of the
uminal type, and are usually ER/PR positive.4 The median age of
reast cancer onset ranges from 40 to 50 years in BRCA1 and
RCA2 carriers compared with 60–70 years in sporadic cases.5,6
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Clinical Pra
● The ideal management of patients carriers of the
Breast Cancer gene mutation in clinical practice
(BRCA)1 or BRCA2 mutations is unknown.
● Prophylactic mastectomy and oophorectomy reduces
the risk of invasive breast cancer in patients with
BRCA1 and BRCA2.
● The risk of invasive breast cancer is not completely elim-
inated by prophylactic mastectomy and oophorectomy.
● We report the case of a patient who underwent pro-
phylactic total mastectomy and oophorectomy and
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We report the striking case of a 60-year-old woman who presented
with extensive bone metastasis and carcinomatous meningitis of
breast cancer origin, 15 years after prophylactic total bilateral mas-
tectomy and oophorectomy.
The patient is a 60-year-old woman who underwent prophylactic
bilateral total mastectomy and oophorectomy at the age of 45 after
her twin sister was diagnosed with breast cancer in the presence of the
BRCA2 mutation. Pathologic examination of the patient’s breasts
and ovaries was benign. She was in excellent health for 15 years until
she presented with new onset low back pain. On physical examina-
tion, she had mild tenderness on palpation of the spine, and had no
palpable chest masses or lymphadenopathy. A magnetic resonance
imaging (MRI) scan of the spine showed cervical, thoracic, and lum-
bar enhancement with mottled appearance. Laboratory workup re-
vealed a normal serum protein electrophoresis and free light chains
that were within normal limits. She has had a normal colonoscopy a
year before presentation. Tumor markers revealed an elevated carci-
noembryonic antigen at 36 ng/mL (normal,  3 ng/mL), and ele-
vated Cancer Antigen (CA)27–29 at 617 U/mL (normal,  38
/mL) and a normal CA125. A computed tomography scan of the
hest, abdomen, and pelvis revealed no abnormality except for dif-
usely mottled appearance of the osseous structures (Figure 1). Two
ice Points
presented with metastatic breast cancer 15 years after
the surgeries.
● To our knowledge this is the first case report of
metastatic breast cancer presenting after mastec-
tomy and oophorectomy without evidence of a pri-
mary tumor and the first case report of carcinoma-
tous meningitis as a presenting sign of metastatic
breast cancer after prophylactic mastectomy and
oophorectomy.
© 2012 Elsevier Inc. All rights reserved.
s, Carcinomatous meningitisct
50-3ays later, the patient presented to our emergency department with
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severe headache, nausea, and vomiting. An MRI scan of the brain
revealed bilateral calvarial and clival lesions, along with evidence of
mild hydrocephalus and transependymal cerebrospinal fluid seepage
concerning for metastatic bone metastasis and leptomeningeal carci-
nomatosis (Figure 2). Cytology of the cerebrospinal fluid derived
from a lumbar puncture was positive for metastatic carcinoma.
A bone marrow core biopsy showed tumor cells that were Mak
6 and CK7 positive, negative for chromogranin, synaptophysin,
Figure 1 A Diffusely Mottled Appearance of the Osseous Struc
Pelvis (B)
A
Figure 2 A Magnetic Resonance Imaging Scan of the Brain
Shows Bilateral Calvarial and Clival Lesions and
Mild Hydrocephalus and Transependymal
Cerebrospinal Fluid Seepage Concerning for
Metastatic Bone Metastasis and Leptomeningeal
CarcinomatosisCD 56, CD 10, RCC, and CK20; ER positive at 90%, and PRpositive at 70%, suggestive of metastatic carcinoma of breast pri-
mary (Figure 3). Fluorescence in situ hybridization analysis for
HER-2 neu was negative.
The patient underwent intrathecal chemotherapy with weekly
methotrexate for 8 consecutive weeks with persistent positive cytol-
ogy. Fifteen additional doses of weekly intrathecal thiotepa were
administered. Her treatment currently consists of an aromatase in-
hibitor and zoledronic acid. She is clinically doing well and is symp-
tom-free, 16 months after her diagnosis.
Discussion
With the increasing use of genetic testing, more women at high
risk are identified and there are no set guidelines on the ideal man-
agement strategy for patients who carry the BRCA mutations. Cur-
rent options include close surveillance, mastectomy, oophorectomy,
mastectomy and oophorectomy, and/or chemoprevention.
A randomized clinical trial comparing these options is not feasible
for obvious ethical considerations. It is estimated that approximately
50% of BRCA mutation carriers chose bilateral prophylactic mastec-
tomy but the data on breast cancer reduction after mastectomy are
limited.7 The types of mastectomy include a subcutaneous mastec-
tomy with preservation of the nipple and areola, a total mastectomy
which includes removal of the breasts and underlying skin, a modi-
fied radical mastectomy which includes a total mastectomy and ax-
illary dissection, and a radical mastectomy which includes a modified
radical mastectomy and removal of the pectoralis muscle.
Hartmann et al conducted a retrospective study of 639 women
with a family history of breast cancer who underwent a prophylactic
mastectomy at the Mayo Clinic between 1963 and 1990.8 Breast
cancer developed in 7 women after subcutaneous prophylactic mas-
tectomy. Of those, 6 were confined to the chest wall and 1 presented
with metastatic breast cancer to the bones 12 years after the prophy-
lactic mastectomy with no chest wall involvement. However, none of
the 64 patients who underwent total mastectomy developed breast
cancer. Data from this study suggested that bilateral prophylactic
mastectomy is associated with 90% reduction in breast cancer inci-
is Seen on the Computed Tomography of the Chest (A) and
Bturesdence and mortality in women at high risk of breast cancer.
Clinical Breast Cancer December 2012 451
b
r
r
B
B
g
3
o
l
p
Metastatic Breast Cancer 15 Years After Total Mastectomy
452Meijers-Heijboer et al conducted a prospective study of 139 pa-
tients with either BRCA1 or BRCA2 mutation who entered the
study without breast cancer.9 Seventy-six of those patients under-
went a prophylactic bilateral mastectomy and 63 remained under
surveillance. None of the mastectomy patients developed breast can-
cer but 8 of the patients who remained under surveillance did de-
velop breast cancer. The authors of the study concluded a 100% risk
reduction among patients who underwent prophylactic mastectomy.
However the study was limited by short follow-up with a mean of 2.9
years.
The Prevention and Observation of Surgical Endpoints (PROSE)
study was a case control study of 483 female carriers of the BRCA1 or
2 mutations of which 105 underwent prophylactic mastectomy and
368 did not.10 After a mean follow-up of 6.4 years, 2 of the patients
who underwent prophylactic mastectomy developed breast cancer;
both had undergone a subcutaneous mastectomy. The first patient
had a BRCA2 mutation and developed breast cancer in an axillary
node 2 years after mastectomy, and the other had a BRCA1 mutation
and developed breast cancer in the residual breast tissue 9 years after
the mastectomy. There was a relative breast cancer risk reduction of
95% in women who had undergone prophylactic salpingo-oopho-
rectomy and 90% risk reduction in those who only had a mastectomy
with ovaries left intact.
Domchek et al conducted a large prospective study of 2482 pa-
tients who were carriers of the BRCA1 or BRCA2 mutation.11 No
reast cancer was identified in the patients who underwent risk-
educing mastectomy. In addition, women who underwent a risk-
educing oophorectomy had a lower risk of breast cancer in both
RCA1 and BRCA2 carriers.
Kauff et al conducted a prospective study of 170 patients with
RCA1 or BRCA2 mutations who chose either risk-reducing salpin-
o-oophorectomy or close surveillance.12 Breast cancer developed in
out of the 98 women who chose salpingo-oophorectomy and in 8
f the 72 women who chose close surveillance.
A case report of a 72-year-old woman who underwent a prophy-
Figure 3 A Bone Marrow Core Biopsy Shows Tumor Cells That
(B), Suggestive of Metastatic Carcinoma of Breast Pr
Aactic subcutaneous mastectomy 30 years before presentation was
Clinical Breast Cancer December 2012ublished in 1997.13 This patient was noted to have a right supra-
clavicular mass and extensive bone metastasis and postmortem ex-
amination revealed a mass underneath the nipple. Another case re-
port was published in 2009 of a 28-year-old woman with BRCA1
mutation who underwent a prophylactic total mastectomy and pre-
sented 5 years later with a subpectoral mass, biopsy proven to be of
breast origin, hinting to the possibility of a tumor arising from resid-
ual breast tissue.14
To our knowledge, this is the first case report of metastatic breast
cancer presenting after total mastectomy and prophylactic oophorec-
tomy with no evidence of primary tumor and the first case report of
carcinomatous meningitis as presenting symptom of metastatic
breast cancer after prophylactic mastectomy.
Conclusion
In conclusion, our patient is doing well and is responding to letro-
zole now 16 months after her diagnosis. She received her last intra-
thecal treatment 4 months ago and is now symptom-free. She is an
example of women at high risk of developing breast cancer who was
counseled about the significant risk reduction of bilateral prophylac-
tic mastectomy and oophorectomy. However, our case report illus-
trates that the risk of breast cancer is not completely eliminated by
prophylactic surgery and this adds to the complexity of the decision.
Total mastectomy seems to provide additional risk reduction of re-
current breast cancer as compared with the older technique of sub-
cutaneous mastectomy. Additional data would be needed to further
define the role of various surgical techniques of mastectomy as well as
the role of bilateral oophorectomy in prevention of cancer in this very
high risk population.
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